iShares Biotechnology ETF
561 hedge funds and large institutions have $5.46B invested in iShares Biotechnology ETF in 2017 Q2 according to their latest regulatory filings, with 87 funds opening new positions, 195 increasing their positions, 175 reducing their positions, and 40 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding in top 10
Funds holding in top 10: →
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
8% more capital invested
Capital invested by funds: $5.06B → $5.46B (+$397M)
8.55% less ownership
Funds ownership: 177.99% → 169.44% (-8.6%)
17% less call options, than puts
Call options by funds: $875M | Put options by funds: $1.05B
Holders
561
Holding in Top 10
33
Calls
$875M
Puts
$1.05B
Top Buyers
| 1 | +$156M | |
| 2 | +$104M | |
| 3 | +$93.7M | |
| 4 |
SIG
Senator Investment Group
New York
|
+$93M |
| 5 |
AL
Appaloosa LP
Short Hills,
New Jersey
|
+$72.9M |
Top Sellers
| 1 | -$190M | |
| 2 | -$121M | |
| 3 | -$111M | |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$98.3M |
| 5 |
BNP Paribas Financial Markets
Paris,
France
|
-$94M |